Traws Pharma financials
$0.6260+8.12%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $2.8M | $226.0K |
| Gross profit | $2.8M | $226.0K |
| Gross margin | 100.0% | 100.0% |
| Operating income | -$17.9M | -$142.4M |
| Net income | $6.9M | -$54.7M |
| Net margin | 246.1% | −24192.0% |
| Diluted EPS | $0.82 | $-35.21 |
| EBITDA | -$17.8M | -$24.9M |
| Operating cash flow | -$18.2M | -$29.8M |
| Free cash flow | -$20.8M | -$33.4M |
| Diluted shares | 8.4M | 1.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $3.8M | $21.3M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $10.6M | $25.0M |
| Total liabilities | $11.2M | $56.6M |
| Shareholders' equity | -$629.0K | -$31.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology